modelMethyldopaLevorotatory
Extends from Pharmacolibrary.Drugs.ATC.C.C02AB01.
Information
| name: | MethyldopaLevorotatory | |
| ATC code: | C02AB01 | route: | oral |
| compartments: | 1 | |
| dosage: | 250 | mg |
| volume of distribution: | 1.3 | L |
| clearance: | 38 | ml/min |
| other parameters in model implementation | ||
Methyldopa is a centrally acting antihypertensive agent, primarily used in the management of hypertension, especially in pregnant women (pre-eclampsia). It functions as a prodrug, metabolized to alpha-methylnorepinephrine, an alpha-2 adrenergic agonist. Methyldopa is approved and used clinically, especially for hypertension in pregnancy.
Pharmacokinetics
Pharmacokinetic parameters for healthy adult volunteers following single oral dose administration.
References
Othman, AA, & Dutta, S (2014). Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. British journal of clinical pharmacology 78(1) 94–105. DOI:10.1111/bcp.12324 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24433449
Cabreira, V, et al., & Massano, J (2019). Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review. Drugs 79(6) 593–608. DOI:10.1007/s40265-019-01098-w PUBMED:https://pubmed.ncbi.nlm.nih.gov/30905034
Stocchi, F, & Vacca, L (2019). A systematic review on the clinical experience with melevodopa/carbidopa fixed combination in patients with Parkinson disease. Minerva medica 110(6) 575–585. DOI:10.23736/S0026-4806.19.06330-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31965781
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)